Aligos Therapeutics, Inc. Common Stock (ALGS) is a publicly traded Healthcare sector company. As of September 2, 2026, ALGS trades at $6.42 with a market cap of $36.59M and a P/E ratio of -0.81. ALGS moved +0.00% today. Year to date, ALGS is -33.30%; over the trailing twelve months it is -42.66%. Its 52-week range spans $3.76 to $37.12. Analyst consensus is strong buy with an average price target of $72.50. Rallies surfaces ALGS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for ALGS shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $6.42 |
| Market Cap | $36.59M |
| P/E Ratio | -0.81 |
| EPS | $-7.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $37.12 |
| 52-Week Low | $3.76 |
| Volume | 30.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $31.52M |
| Net Income | $-75.96M |
| Gross Margin | 0.00% |
4 analysts cover ALGS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $72.50.